Luopu Biological-B (02157.HK) achieved its first-ever profit in the first half of the year, with revenue growing significantly by 2.5 times. The research and development pipeline has been fruitful.

Wisdom Finance and Economics APP News, Lepu Medical-B (02157.HK) released its interim performance for the six months ending June 30, 2025. The group achieved a revenue of 466 million yuan (same unit), an increase of 249.59% year-on-year; the net profit attributable to shareholders of the company was 41.745 million yuan, compared to a loss of 192 million yuan in the same period last year; basic earnings per share were 0.02 yuan.